Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2019-10-28 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Notice of release of securities from Mandatory Escrow 1
Regulatory Filings Classification · 95% confidence The document is a notice about the release of securities from mandatory escrow, specifying the number and type of securities being released and the date of release. It also mentions an application for quotation of shares. The document is short (1654 characters) and serves as an announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-10-28 English
Appendix 4C - September 2019 quarter 5 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated statements of cash flows for the current quarter and year to date, payments to directors and related parties, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The presence of substantive financial data and quarterly period references indicates this is a quarterly financial report. The document is 8762 characters long, which is sufficient to contain detailed financial information rather than just an announcement. The document is not an earnings release or an annual report but a comprehensive quarterly report with financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2019
2019-10-28 English
Sales Note to accompany Appendix 4C 2 pages 150.2KB
Capital/Financing Update Classification · 90% confidence The document is a sales update for a specific product (TLX591-CDx kit) by Telix Pharmaceuticals, providing quarterly sales figures, order growth, and operational details. It includes financial figures for Q3 and year-to-date patient doses produced but does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). The document is relatively short (4781 characters) and reads like a business update or capital/financing activity related to sales performance rather than a full financial report. It is not an earnings release (ER) since it lacks key financial highlights or earnings metrics, nor is it a regulatory filing or report publication announcement. The focus on sales growth and order values aligns best with a Capital/Financing Update (CAP) category, which covers updates on company fundraising, financing activities, or capital structure changes, including sales performance updates relevant to capital activities. Therefore, the most appropriate classification is CAP with high confidence.
2019-10-28 English
Telix and GE data - 68Ga supply for prostate cancer imaging 2 pages 140.9KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of integration of GE Healthcare's cyclotron-based gallium production data with Telix Pharmaceuticals' regulatory package for a prostate cancer imaging product. It discusses collaboration, validation data, regulatory submissions preparation, and market supply chain improvements. There are no financial statements, detailed financial performance data, nor is it a transcript, report, or filing of financial results. The document is an update on a capital/financing-related collaboration and regulatory preparation, but it does not announce fundraising or capital structure changes directly. It is not an annual or interim report, audit report, or earnings release. The document is a corporate announcement about a strategic collaboration and regulatory progress, fitting best under Capital/Financing Update (CAP) as it relates to the company's product development and regulatory strategy impacting future capital and market positioning. The document length is 4624 characters, which is not extremely short, and it contains substantive information rather than just a report publication announcement or certification. Therefore, the best classification is CAP with high confidence.
2019-10-13 English
David Cade appointed Chief Business Officer and Head of IR 2 pages 135.1KB
Board/Management Information Classification · 95% confidence The document is a company announcement about the appointment of a new Chief Business Officer and Head of Investor Relations. It contains no financial statements, no regulatory filings, no voting results, no legal proceedings, no capital changes, and no detailed financial or operational data. The content focuses on management changes and executive team updates. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4015 characters, which is consistent with a typical management announcement rather than a full report or presentation.
2019-10-06 English
Telix to Acquire European Production Facility 2 pages 145.6KB
Capital/Financing Update Classification · 95% confidence The document is a corporate announcement by Telix Pharmaceuticals Limited regarding the acquisition of a European production facility. It details the terms of the acquisition, strategic rationale, regulatory conditions, and expected benefits. There are no financial statements, quarterly or annual results, or detailed financial data presented. The content focuses on a capital asset acquisition and strategic expansion rather than financial performance or regulatory filings. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions of significant assets.
2019-10-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.